NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy.
Neuropeptide Y is the most potent physiological appetite transducer known. The NPY network is the conductor of the hypothalamic appetite regulating orchestra in the arcuate nucleus-paraventricular nucleus (ARC-PVN) of the hypothalamus. NPY and cohorts, AgrP, GABA and adrenergic transmitters, initiate appetitive drive directly through Y1, Y5, GABAA and alpha1 receptors, co-expressed in the magnocellular PVN (mPVN) and ARC neurons and by simultaneously repressing anorexigenic melanocortin signaling in the ARC-PVN axis. The circadian and ultradian rhythmicities in NPY secretion imprint the daily circadian and episodic feeding patterns. Although a number of afferent hormonal signals from the periphery can directly modulate NPYergic signaling, the reciprocal circadian and ultradian rhythmicities of anorexigenic leptin from adipocytes and orexigenic ghrelin from stomach, encode a corresponding pattern of NPY discharge for daily meal patterning. Subtle and progressive derangements produced by environmental and genetic factors in this exquisitely intricate temporal relationship between the two opposing humoral signals and the NPY network promote hyperphagia and abnormal rate of weight gain culminating in obesity and attendant metabolic disorders. Newer insights at cellular and molecular levels demonstrate that a breakdown of the integrated circuit due both to high and low abundance of NPY at target sites, underlies hyperphagia and increased adiposity. Consequently, interruption of NPYergic signaling at a single locus with NPY receptor antagonists may not be the most efficacious therapy to suppress hyperphagia and obesity. Central leptin gene therapy in rodents has been shown to subjugate, i.e. bring under homeostatic control, NPYergic signaling and suppress the age-related and dietary obesity for extended periods and thus shows promise as a newer treatment modality to curb the pandemic of obesity and metabolic syndrome.
Kalra
S P
SP
Department of Neuroscience, University of Florida, McKnight Brain Institute, PO Box 100244, Gainesville, FL 32610, USA. skalra@mbi.ufl.edu
Kalra
P S
PS
D000818:Animals; D001066:Appetite / Q000502:physiology*; D001111:Arcuate Nucleus of Hypothalamus / Q000378:metabolism; D002940:Circadian Rhythm; D001068:Feeding and Eating Disorders / Q000378:metabolism / Q000628:therapy; D015316:Genetic Therapy; D024821:Metabolic Syndrome / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D009478:Neuropeptide Y / Q000031:analogs & derivatives* / Q000378:metabolism*; D009765:Obesity / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D010286:Paraventricular Hypothalamic Nucleus / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y